Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The number of oral treatments was different between the two groups; no difference was found in other clinical characteristics. (Table 2).Clinical characteristics of the patientsTotal (n = 110) Mean (SD)Modulator therapy group (n = 51) Mean (SD)Non-Modulator therapy group (n = 59) Mean (SD)p*FEV1 (liters)2.43 ± 1.102.45 ± 1.062.41 ± 1.140.730FVC (liters)3.27 ± 1.233.34 ± 1.193.22 ± 1.270.496FEV1%66.98 ± 27.0868.94 ± 27.6865.28 ± 26.680.517FVC%77.48 ± 25.9080.88 ± 26.8574.54 ± 24.910.189FEV1/FVC73.16 ± 12.7172.44 ± 13.8473.77 ± 11.720.721Number of medications4.31 ± 2.084.50 ± 1.744.15 ± 2.340.131Number of oral medications2.60 ± 1.362.80 ± 1.162.42 ± 1.510.035Number of inhaled medications1.60 ± 1.211.51 ± 1.061.67 ± 1.330.717Number of hospitalizations within the last year0.57 ± 0.920.54 ± 0.920.59 ± 0.930.776Number of patients hospitalized within the last year, n (%)40 (36.4)18 (35.3)22 (37.3)0.828ALT (U/L)22.84 ± 13.5324.05 ± 14.5121.75 ± 12.610.384AST (U/L)22.93 ± 7.6923.45 ± 8.822.47 ± 6.590.519ALP (U/L)107.75 ± 54.58100.62 ± 39.73114.12 ± 64.760.19GGT (U/L)24.45 ± 22.9824.50 ± 18.9724.40 ± 26.230.981Total bilirubin (mg/dL)0.72 ± 0.410.77 ± 0.430.67 ± 0.370.250Albumin (g/dL)4.24 ± 0.464.28 ± 0.364.21 ± 0.530.346Creatine kinase (U/L)83.84 ± 51.5093.15 ± 43.9275.51 ± 56.530.071INR0.99 ± 0.110.97 ± 0.071.01 ± 0.130.104Bold indicates statistically significant variableFEV1, First second of forced expiration; FVC, Forced vital capacity; ALT, Alanin aminotransferase; AST, Aspartat aminotransferase; ALP, Alkaline phosphatase; GGT, Gamma-glutamyl transferase; INR, International normalized ratioOral medications: Pancreatic enzyme replacement therapy, multivitamin, ursodeoxycholic acid, vitamin A, vitamin E, vitamin D, vitamin D and calcium, azithromycin, proton pump inhibitors, antacids, beta blocker, bisphosphonates, elexacaftor/tezacaftor/ivacaftor, tezacaftor/ivacaftor, ivacaftor* Comparison of modulator and non-modulator therapy groups

Source: Patients’ characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

A single-center prospective cohort study was conducted between June 2023 and January 2024.

Source: Abstract.

Patients were also evaluated in two groups as modulator and non-modulator groups.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Are adult cystic fibrosis patients satisfied with medication treatment?

Cohort study · Orphanet Journal of Rare Diseases · 2025

Original publication title

Are adult cystic fibrosis patients satisfied with medication treatment?

Esen Deniz Akman; Nadir Yalçın; Oğuz Karcıoğlu; Ebru Damadoğlu; Ali Fuat Kalyoncu; Kutay Demirkan

© The Author(s) 2025

Original publication · Publisher record · CC BY 4.0 · CC0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Treatment satisfaction in adult CF patients is influenced by modulators, treatment burden, and clinical factors, so access to modulators is important. This is the first study to classify DRPs according to PCNE in CF. Clinical pharmacists contribute to the management of CF.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Treatment satisfaction can be described as the patient’s experience in patients with cystic fibrosis (CF). It can be influenced using modulators and clinical characteristics. The aims of this study were to evaluate and compare adult CF patients with and without modulators regarding treatment satisfaction, related factors and to manage their drug related problems (DRPs).

Source: Background

Abstract: What methods does the paper describe?

A single-center prospective cohort study was conducted between June 2023 and January 2024. Treatment Satisfaction Questionnaire for Medication (TSQM 1.4), including effectiveness, side effects, convenience, global satisfaction domains, CF Questionnaire-Revised (CFQ-R), and Medication Adherence Report Scale were applied and assessed with and without modulator therapy groups. The relationship between clinical characteristics and TSQM was analyzed by correlations and regression analysis. Recommendations on DRPs identified by clinical pharmacists were made to the physicians and patients and classified according to Pharmaceutical Care Network Europe (PCNE v9.1).

Source: Methods

Abstract: Results

A total of 110 patients with 51 modulator therapy and 59 without modulator therapy were included. The mean global satisfaction score of modulator users was found to be 19.733 (p < 0.001) points higher than non-users. When the CFQ-R treatment burden score improved by 1point, global satisfaction score increased by 0.233 points (p < 0.001). When the number of hospitalizations increased by 1 day, the global satisfaction score decreased by 4.751 points (p < 0.001). A total of 84 DRPs were identified, and 69 (82.1%) of them were resolved.

Source: Results

Abstract: Conclusions

Treatment satisfaction in adult CF patients is influenced by modulators, treatment burden, and clinical factors, so access to modulators is important. This is the first study to classify DRPs according to PCNE in CF. Clinical pharmacists contribute to the management of CF.

Source: Conclusions
Authors’ abstract

Background

Treatment satisfaction can be described as the patient’s experience in patients with cystic fibrosis (CF). It can be influenced using modulators and clinical characteristics. The aims of this study were to evaluate and compare adult CF patients with and without modulators regarding treatment satisfaction, related factors and to manage their drug related problems (DRPs).

Methods

A single-center prospective cohort study was conducted between June 2023 and January 2024. Treatment Satisfaction Questionnaire for Medication (TSQM 1.4), including effectiveness, side effects, convenience, global satisfaction domains, CF Questionnaire-Revised (CFQ-R), and Medication Adherence Report Scale were applied and assessed with and without modulator therapy groups. The relationship between clinical characteristics and TSQM was analyzed by correlations and regression analysis. Recommendations on DRPs identified by clinical pharmacists were made to the physicians and patients and classified according to Pharmaceutical Care Network Europe (PCNE v9.1).

Results

A total of 110 patients with 51 modulator therapy and 59 without modulator therapy were included. The mean global satisfaction score of modulator users was found to be 19.733 (p < 0.001) points higher than non-users. When the CFQ-R treatment burden score improved by 1point, global satisfaction score increased by 0.233 points (p < 0.001). When the number of hospitalizations increased by 1 day, the global satisfaction score decreased by 4.751 points (p < 0.001). A total of 84 DRPs were identified, and 69 (82.1%) of them were resolved.

Conclusions

Treatment satisfaction in adult CF patients is influenced by modulators, treatment burden, and clinical factors, so access to modulators is important. This is the first study to classify DRPs according to PCNE in CF. Clinical pharmacists contribute to the management of CF.

Publication and source details

Original title: Are adult cystic fibrosis patients satisfied with medication treatment?

Esen Deniz Akman; Nadir Yalçın; Oğuz Karcıoğlu; Ebru Damadoğlu; Ali Fuat Kalyoncu; Kutay Demirkan

Orphanet Journal of Rare Diseases · 2025

© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T05:45:29.481582+00:00

DOI: 10.1186/s13023-025-03676-6 · PMC11993955